Table 1 Patients' characteristics

Characteristic	Value	Standardized difference (%) / Sorror	Standardized difference (%) / Parimon[1]
Median age (range), y	31 (4 to 64)		62
Age < 15 y, no. (%)	57 (20)		
Female patients, no. (%)	117 (41)		0
Diagnosis, no. (%)			
AML	86 (30)	7	
ALL	57 (20)	28	
MM	21 (7)	4	
Sickle cell disease and thalassemic syndromes	16 (6)	*	
NHL	16 (6)	11	
CML	16 (6)	43	
MDS	15 (5)	44	
HD	14 (5)	16	
FA	13 (4)	*	
Other malignancies	13 (4)	29	
Other non malignancies	19 (7)	*48	
Disease risk			
Low	38 (13)		28
Intermediate	156 (55)		57
High	92 (32)		25
Hematopoietic cell source, no. (%)			
Marrow	123 (43)	29	71
PBSC	124 (43)	59	43
Cord blood	20 (7)	*57	*51
Double cord blood	19 (7)	*	*
Donor type, no. (%)			
Matched related	149 (52)	*6	10
Matched unrelated	63 (22)	6	4
Other	74 (26)	*	29
Conditioning regimen, no. (%)			
BU + CY	92 (32)	23	*8
CY + 12 Gy TBI	64 (22)	16	14
2 Gy TBI	25 (9)	11	**93
Fludarabine + 2 Gy TBI	35 (12)	27	**
Fludarabine + EDX or Mel ± SAL	28 (10)	*82	**
Other myeloablative regimen	11 (4)	*	*
Other non myeloablative regimen	31 (11)	*	
GVHD prophylaxis, no. (%)			
CSP + MTX	150 (52)	67	
CSP + MMF	100 (35)	39	
CSP + MP	31 (11)	*52	
CSP alone or MMF + MP	4 (1)	*	

1 development group; * and **: grouped categories